These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 23252945

  • 1. Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression.
    Shi P, Zha J, Guo X, Chen F, Fan Z, Huang F, Meng F, Liu X, Feng R, Xu B.
    Pharmacogenomics; 2013 Jan; 14(1):17-23. PubMed ID: 23252945
    [Abstract] [Full Text] [Related]

  • 2. [Improved treatment results in children with AML: Results of study AML-BFM 93].
    Creutzig U, Berthold F, Boos J, Fleischhack G, Gadner H, Gnekow A, Graubner U, Henze G, Hermann J, Imbach P, Jürgens H, Kabisch H, Körholz D, Niemeyer CM, Reinhardt D, Reiter A, Ritter J, Spaar HJ, Zimmermann M, AML-BFM-Studien-Gruppe.
    Klin Padiatr; 2001 Jan; 213(4):175-85. PubMed ID: 11528551
    [Abstract] [Full Text] [Related]

  • 3. A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia.
    Wiernik PH, Case DC, Periman PO, Arlin ZA, Weitberg AB, Ritch PS, Todd MB.
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):25-9. PubMed ID: 2928807
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia.
    Masaoka T, Ogawa M, Yamada K, Kimura K, Ohashi Y.
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):12-7. PubMed ID: 8916311
    [Abstract] [Full Text] [Related]

  • 6. A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia.
    Vogler WR, Velez-Garcia E, Omura G, Raney M.
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):21-4. PubMed ID: 2648581
    [No Abstract] [Full Text] [Related]

  • 7. Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine.
    Wiedower E, Jamy O, Martin MG.
    Anticancer Res; 2015 Nov; 35(11):6287-90. PubMed ID: 26504064
    [Abstract] [Full Text] [Related]

  • 8. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
    Baer MR, Christiansen NP, Frankel SR, Brunetto VL, Mrózek K, Bloomfield CD, Herzig GP.
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
    [Abstract] [Full Text] [Related]

  • 9. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
    Reiffers J, Huguet F, Stoppa AM, Molina L, Marit G, Attal M, Gastaut JA, Michallet M, Lepeu G, Broustet A, Pris J, Maraninchi D, Hollard D, Fabères C, Mercier M, Hurteloup P, Danel P, Tellier Z, Berthaud P.
    Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852
    [Abstract] [Full Text] [Related]

  • 10. [A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group].
    Masaoka T, Ogawa M, Yamada K, Kimura K, Ohhashi Y.
    Gan To Kagaku Ryoho; 1993 Oct; 20(13):1995-2005. PubMed ID: 8215474
    [Abstract] [Full Text] [Related]

  • 11. Risk-adapted induction and consolidation therapy in adults with de novo AML aged </= 60 years: results of a prospective multicenter trial.
    Heil G, Krauter J, Raghavachar A, Bergmann L, Hoelzer D, Fiedler W, Lübbert M, Noens L, Schlimok G, Arnold R, Kirchner H, Ganser A.
    Ann Hematol; 2004 Jun; 83(6):336-44. PubMed ID: 15034758
    [Abstract] [Full Text] [Related]

  • 12. Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA.
    Petti MC, Mandelli F.
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):10-5. PubMed ID: 2928805
    [No Abstract] [Full Text] [Related]

  • 13. Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.
    Berman E, Raymond V, Gee T, Kempin SJ, Gulati S, Andreeff M, Kolitz J, Gabrilove J, Heller G, Young CW.
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):30-4. PubMed ID: 2928808
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
    Liu H, Fu R, Li L, Wang G, Song J, Ruan E, Wang H, Wu Y, Wang X, Ding K, Shao Z.
    Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823
    [Abstract] [Full Text] [Related]

  • 15. The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials.
    Wang H, Xiao X, Xiao Q, Lu Y, Wu Y.
    Medicine (Baltimore); 2020 Jun 12; 99(24):e20094. PubMed ID: 32541448
    [Abstract] [Full Text] [Related]

  • 16. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
    Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Mattiuzzi GN, Tsimberidou AM, Albitar M, O'Brien SM, Estey E.
    Leuk Res; 2005 Jun 12; 29(6):649-52. PubMed ID: 15863204
    [Abstract] [Full Text] [Related]

  • 17. Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia.
    Lee JH, Kim H, Joo YD, Lee WS, Bae SH, Zang DY, Kwon J, Kim MK, Lee J, Lee GW, Lee JH, Choi Y, Kim DY, Hur EH, Lim SN, Lee SM, Ryoo HM, Kim HJ, Hyun MS, Lee KH, Cooperative Study Group A for Hematology.
    J Clin Oncol; 2017 Aug 20; 35(24):2754-2763. PubMed ID: 28632487
    [Abstract] [Full Text] [Related]

  • 18. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group.
    Br J Haematol; 1998 Oct 20; 103(1):100-9. PubMed ID: 9792296
    [Abstract] [Full Text] [Related]

  • 19. High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia.
    Low M, Lee D, Coutsouvelis J, Patil S, Opat S, Walker P, Schwarer A, Salem H, Avery S, Spencer A, Wei A.
    Intern Med J; 2013 Mar 20; 43(3):294-7. PubMed ID: 22757980
    [Abstract] [Full Text] [Related]

  • 20. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group.
    Ruutu T, Almqvist A, Hallman H, Honkanen T, Järvenpää E, Järventie G, Koistinen P, Koivunen E, Lahtinen R, Lehtinen M.
    Leukemia; 1994 Jan 20; 8(1):11-5. PubMed ID: 8289475
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.